Bioventus (BVS) Common Equity (2020 - 2026)

Bioventus' Common Equity history runs 7 years deep, the most recent figure standing at $234.3 million for Q1 2026.

• Quarterly Common Equity rose 26.3% year-over-year to $234.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $234.3 million (up 26.3% YoY) and the FY2025 annual result came in at $184.1 million, down 0.81% from the prior year.
• Common Equity was $234.3 million for Q1 2026 at Bioventus, up from $184.1 million in the prior quarter.
• Across five years, Common Equity topped out at $593.8 million in Q2 2022 and bottomed at $166.1 million in Q3 2025.
• A 5-year average of $277.7 million and a median of $221.1 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity soared 169.91% — and 2023, when it sank 60.59%.
• Bioventus' Common Equity stood at $412.2 million in 2022, then sank by 46.36% to $221.1 million in 2023, then fell by 16.06% to $185.6 million in 2024, then dropped by 0.81% to $184.1 million in 2025, then grew by 27.25% to $234.3 million in 2026.
• Business Quant data shows BVS's Common Equity at $234.3 million in Q1 2026, $184.1 million in Q4 2025, and $166.1 million in Q3 2025.